Clinical nonmotor aspect of A2A antagonist in PD treatment.
The chapter discusses with clinical case study if adenosine A2A receptor antagonist, as a novel therapeutic class for symptomatic improvement of Parkinson's disease (PD), can also be expected to have an improvement of nonmotor symptoms related with PD.